9.52
-0.98 (-9.33%)
| Previous Close | 10.50 |
| Open | 10.50 |
| Volume | 15,191,225 |
| Avg. Volume (3M) | 9,432,898 |
| Market Cap | 9,445,880,832 |
| Price / Sales | 4.06 |
| Price / Book | 5.23 |
| 52 Weeks Range | |
| Earnings Date | 26 Mar 2025 |
| Operating Margin (TTM) | -17,980.98% |
| Diluted EPS (TTM) | -0.330 |
| Quarterly Revenue Growth (YOY) | -87.30% |
| Total Debt/Equity (MRQ) | 0.39% |
| Current Ratio (MRQ) | 12.88 |
| Operating Cash Flow (TTM) | -341.58 M |
| Levered Free Cash Flow (TTM) | -208.35 M |
| Return on Assets (TTM) | -10.96% |
| Return on Equity (TTM) | -13.97% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (HK) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | ASCLETIS-B | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | -0.25 |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| ASCLETIS-B | 9 B | - | - | 5.23 |
| 3SBIO | 49 B | 0.82% | 22.31 | 4.02 |
| KEYMED BIO-B | 12 B | - | - | 6.29 |
| HAOHAI BIOTEC | 12 B | 3.41% | 13.63 | 0.970 |
| INNOVENT BIO | 167 B | - | 132.16 | 10.62 |
| AKESO | 138 B | - | - | 18.31 |
|
Ascletis Pharma Inc is an investment holding company. Along with its subsidiaries, it is engaged in the research and development, production, marketing, and sale of pharmaceutical products. It has three marketed products, i.e. Ritonavir tablets, GANOVO, and ASCLEVIR. It also has other drug candidates in its pipeline in their different stages of development such as ASC22, ASC10, ASC11, and ASC40 among others. Geographically, it operates in Mainland China and other regions. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Value |
| % Held by Insiders | 74.38% |
| % Held by Institutions | 0.74% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |